Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2012 1
2013 3
2014 13
2015 10
2016 7
2017 6
2018 5
2019 5
2020 7
2021 6
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Campbell BB, et al. Among authors: fuligni f. Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19. Cell. 2017. PMID: 29056344 Free PMC article.
Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis.
Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND, Hatkar R, Blay S, Chen D, Novokmet A, Fuligni F, Tran J, de Borja R, Agarwal H, Waldman L, Abegglen LM, Albertson D, Finlay JL, Hansford JR, Behjati S, Villani A, Gerstung M, Alexandrov LB, Somers GR, Schiffman JD, Rotter V, Malkin D, Shlien A. Light N, et al. Among authors: fuligni f. Nat Commun. 2023 Jan 5;14(1):77. doi: 10.1038/s41467-022-35727-y. Nat Commun. 2023. PMID: 36604421 Free PMC article.
The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations.
Villani A, Davidson S, Kanwar N, Lo WW, Li Y, Cohen-Gogo S, Fuligni F, Edward LM, Light N, Layeghifard M, Harripaul R, Waldman L, Gallinger B, Comitani F, Brunga L, Hayes R, Anderson ND, Ramani AK, Yuki KE, Blay S, Johnstone B, Inglese C, Hammad R, Goudie C, Shuen A, Wasserman JD, Venier RE, Eliou M, Lorenti M, Ryan CA, Braga M, Gloven-Brown M, Han J, Montero M, Spatare F, Whitlock JA, Scherer SW, Chun K, Somerville MJ, Hawkins C, Abdelhaleem M, Ramaswamy V, Somers GR, Kyriakopoulou L, Hitzler J, Shago M, Morgenstern DA, Tabori U, Meyn S, Irwin MS, Malkin D, Shlien A. Villani A, et al. Among authors: fuligni f. Nat Cancer. 2023 Feb;4(2):203-221. doi: 10.1038/s43018-022-00474-y. Epub 2022 Dec 30. Nat Cancer. 2023. PMID: 36585449 Free PMC article.
Widespread hypertranscription in aggressive human cancers.
Zatzman M, Fuligni F, Ripsman R, Suwal T, Comitani F, Edward LM, Denroche R, Jang GH, Notta F, Gallinger S, Selvanathan SP, Toretsky JA, Hellmann MD, Tabori U, Huang A, Shlien A. Zatzman M, et al. Among authors: fuligni f. Sci Adv. 2022 Nov 25;8(47):eabn0238. doi: 10.1126/sciadv.abn0238. Epub 2022 Nov 23. Sci Adv. 2022. PMID: 36417526 Free PMC article.
PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome.
Pileri A, Tabanelli V, Fuligni F, Agostinelli C, Guglielmo A, Sabattini E, Grandi V, Pileri SA, Pimpinelli N. Pileri A, et al. Among authors: fuligni f. Ital J Dermatol Venerol. 2022 Aug;157(4):355-362. doi: 10.23736/S2784-8671.22.07275-9. Epub 2022 Apr 4. Ital J Dermatol Venerol. 2022. PMID: 35373781 Free article.
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival.
Anderson ND, Babichev Y, Fuligni F, Comitani F, Layeghifard M, Venier RE, Dentro SC, Maheshwari A, Guram S, Wunker C, Thompson JD, Yuki KE, Hou H, Zatzman M, Light N, Bernardini MQ, Wunder JS, Andrulis IL, Ferguson P, Razak ARA, Swallow CJ, Dowling JJ, Al-Awar RS, Marcellus R, Rouzbahman M, Gerstung M, Durocher D, Alexandrov LB, Dickson BC, Gladdy RA, Shlien A. Anderson ND, et al. Among authors: fuligni f. Nat Commun. 2021 Jul 23;12(1):4496. doi: 10.1038/s41467-021-24677-6. Nat Commun. 2021. PMID: 34301934 Free PMC article.
Enly: Improving Draft Genomes through Reads Recycling.
Fondi M, Orlandini V, Corti G, Severgnini M, Galardini M, Pietrelli A, Fuligni F, Iacono M, Rizzi E, De Bellis G, Fani R. Fondi M, et al. Among authors: fuligni f. J Genomics. 2014 Apr 5;2:89-93. doi: 10.7150/jgen.7298. eCollection 2014. J Genomics. 2014. PMID: 25031660 Free PMC article.
Second neoplasm in cutaneous T-cell lymphoma patients: a marker of worse prognosis?
Pileri A, Guglielmo A, Fuligni F, Lastrucci I, Patrizi A, Pimpinelli N; Italian Lymphoma Foundation (FIL) - Cutaneous Lymphoma Task Force. Pileri A, et al. Among authors: fuligni f. Ital J Dermatol Venerol. 2021 Aug;156(4):484-488. doi: 10.23736/S2784-8671.19.06510-6. Epub 2019 Dec 4. Ital J Dermatol Venerol. 2021. PMID: 31804054 Free article.
59 results